悪性グリオーマの標準治療と新しい治療

DOI Web Site

書誌事項

タイトル別名
  • Standard therapy and new standards for malignant gliomas
  • アクセイ グリオーマ ノ ヒョウジュン チリョウ ト アタラシイ チリョウ

この論文をさがす

抄録

Extensive resection of malignant gliomas without compromising neuronal function has been believed to prolong the survival of the patients. Among the therapeutic triad, radiation therapy has been shown to improve overall survival. Recent publication of a positive phase 3 trial comparing radiation therapy (RT) alone with RT and temozolomide chemotherapy in patients with glioblastomas introduced a new standard chemotherapy. Significan atdvantage was detected of the patients who have methylated MGMT promoter in the treatment of temozolomide. On the other hand, oligodendrogliomas with 1p/19q loss was reported to have good clinical course without PCV chemotherapy T. heses examples show that genomic analyses such as 1p/19qd eletion or MGMT status in glial tumors are necessary to predict sensitivity against chemotherapy.

収録刊行物

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ